Convelo Therapeutics

About:

Convelo Therapeutics specializes in developing medicines to regenerate myelin around nerve cells and restore function

Twitter/X: ConveloTx

Top Investors: Zanite Ventures

Description:

Convelo Therapeutics specializes in developing medicines to regenerate myelin around nerve cells and restore function. The company's scientists have developed an innovative platform to identify novel candidate treatments capable of directly stimulating stem cells in the central nervous system to form new myelin.

Total Funding Amount:

$20.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cleveland, Ohio, United States

Founded Date:

2016-01-01

Founders:

Drew Adams, Paul Tesar

Number of Employees:

11-50

Last Funding Date:

2022-12-08

IPO Status:

Private

Industries: